Similarly to other cancer types, also in SGC both AR and HER2 may be targeted by hormone therapy (5–7), and anti-HER2 agents as trastuzumab (8, 9), trastuzumab plus pertuzumab (10), ado-trastuzumab emtansine (11, 12), trastuzumab deruxtecan (13). Here, ERBB2 is linked to cancer.